logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5137.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5137.produseast1
Showing 1 - 20 of 99 Items
Showing 1 - 20 of 99 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Review

Kala-azar elimination in India: Reflections on success and sustainability

Pandey DK, Alvar J, den Boer M, Jain S, Gill N,  et al.
2025-03-03 • International Health
2025-03-03 • International Health

The incidence and mortality of kala-azar (KA, visceral leishmaniasis) in India have fallen drastically in the past few years, and in 2023 the reported KA incidence reached the thresho...

Journal Article
|
Research

Patient insights research exploring disease awareness, patient life experience, and current management of visceral leishmaniasis in Bihar, India

Sundar S, Alves F, Ritmeijer K, den Boer M, Forsyth C,  et al.
2025-02-25 • PLOS Neglected Tropical Diseases
2025-02-25 • PLOS Neglected Tropical Diseases

BACKGROUND

Visceral leishmaniasis (VL) is a vector-borne disease caused by Leishmania parasites and transmitted by sand fly bites, targeted for elimination in I...

Journal Article
|
Commentary

Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in eastern Africa

Chu WY, Verrest L, Younis BM, Musa AM, Mbui J,  et al.
2024-12-16 • Journal of Infectious Diseases
2024-12-16 • Journal of Infectious Diseases

Treatment regimens for post-kala-azar dermal leishmaniasis (PKDL) are usually extrapolated from those for visceral leishmaniasis (VL), but drug pharmacokinetics (PK) can differ due to...

Journal Article
|
Research

Prediction of visceral leishmaniasis development in a highly exposed HIV cohort in Ethiopia based on Leishmania infection markers: results from the PreLeisH study

van Griensven J, van Henten S, Kibret A, Kassa M, Beyene H,  et al.
2024-12-01 • EBioMedicine
2024-12-01 • EBioMedicine

BACKGROUND

Tar...

Journal Article
|
Research

The economic burden of visceral leishmaniasis and barriers to accessing healthcare in Tigray, North Ethiopia: A field based study

Tessema SB, Hagos T, Kehasy G, Paintain L, Adera C,  et al.
2024-10-15 • PLOS Neglected Tropical Diseases
2024-10-15 • PLOS Neglected Tropical Diseases

BACKGROUND

Visceral leishmaniasis (VL) is an important public health problem, which mainly affects the poor rural dwelling communities in Low- and Middle-Income...

Journal Article
|
Research

A preliminary indication that HLA-A*03:01 may be associated with visceral leishmaniasis development in people living with HIV in Ethiopia

de Vrij N, Vandoren R, Ramadan K, Van Hul A, Ceulemans A,  et al.
2024-09-30 • PLOS Neglected Tropical Diseases
2024-09-30 • PLOS Neglected Tropical Diseases

Human immunodeficiency virus (HIV) co-infection is a major challenge for visceral leishmaniasis (VL) control, particularly in Ethiopia where the incidence of both pathogens is high. V...

Journal Article
|
Review

Paving the way for affordable and equitable liposomal amphotericin B access worldwide

Lee JSF, Cohen RM, Khan RA, Burry J, Casas EC,  et al.
2024-09-01 • Lancet Global Health
2024-09-01 • Lancet Global Health
Journal Article
|
Research

A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh

Sundar S, Pandey K, Mondal D, Madhukar M, Kamal Topno R,  et al.
2024-06-20 • PLOS Neglected Tropical Diseases
2024-06-20 • PLOS Neglected Tropical Diseases
BACKGROUND
In Southeast Asia, treatment is recommended for all patients with post-kala-azar dermal leishmaniasis (PKDL). Adherence to the first-line regimen, twelve weeks of miltefos...
Conference Material
|
Video

Prognostic models predicting clinical outcomes in patients diagnosed with visceral leishmaniasis: a systematic review

Wilson JM
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|
Slide Presentation

Prognostic models predicting clinical outcomes in patients diagnosed with visceral leishmaniasis: a systematic review

Wilson JM, Chowdhury F, Hassan S, Harriss E, Alves F,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Conference Material
|
Abstract

Prognostic models predicting clinical outcomes in patients diagnosed with visceral leishmaniasis: a systematic review

Wilson JM, Chowdhury F, Hassan S, Harriss E, Alves F,  et al.
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
INTRODUCTION
Visceral leishmaniasis (VL) is a neglected tropical disease prevalent in populations affected by poverty, war, and famine. Without effective treatment, death is the norm...
Conference Material
|
Poster

Descriptions of a paediatric visceral leishmaniasis cohort and their outcomes in Upper Nile State, South Sudan

Litster M, Sangma M, Kihara M, Nanclares C, de Bartolome Gisbert F,  et al.
2024-05-03 • MSF Paediatric Days 2024
2024-05-03 • MSF Paediatric Days 2024
Journal Article
|
Pre-Print

HLA-A*03:01 is associated with visceral leishmaniasis development in people living with HIV in Ethiopia

de Vrij N, Vandoren R, Ramadan K, Van Hul A, Kassa M,  et al.
2024-02-18 • medRxiv
2024-02-18 • medRxiv
Human immunodeficiency virus (HIV) co-infection is a major challenge for visceral leishmaniasis (VL) control, particularly in Ethiopia where the incidence of both pathogens is high. VL-H...
Journal Article
|
Case Report/Series

Chronic high level parasitemia in HIV-infected individuals with or without visceral leishmaniasis in an endemic area in North-West Ethiopia: potential superspreaders?

van Griensven J, van Henten S, Kibret A, Kassa M, Beyene H,  et al.
2024-01-09 • Clinical Infectious Diseases
2024-01-09 • Clinical Infectious Diseases
BACKGROUND
HIV patients with recurrent visceral leishmaniasis (VL) could potentially drive Leishmania transmission in areas with anthroponotic transmission such as East-Africa, but s...
Journal Article
|
Review

The status of combination therapy for visceral leishmaniasis: an updated review

van Griensven J, Dorlo TPC, Diro EGJ, Costa CH, Burza S
2024-01-01 • Lancet Infectious Diseases
2024-01-01 • Lancet Infectious Diseases
For the past 15 years, trials of combination therapy options for visceral leishmaniasis have been conducted with the aim of identifying effective, and safe treatment regimens that were s...
Journal Article
|
Protocol

Haematological dynamics following treatment of visceral leishmaniasis: a protocol for systematic review and individual participant data (IPD) meta-analysis

Munir A, Dahal P, Kumar R, Singh-Phulgenda S, Siddiqui NA,  et al.
2023-12-14 • BMJ Open
2023-12-14 • BMJ Open
INTRODUCTION
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30,000 new cases occurring annually. Despite anaemia being a common haematological manifestation of ...
Journal Article
|
Protocol

Host, parasite and drug determinants of clinical outcomes following treatment of visceral leishmaniasis: a protocol for individual participant data meta-analysis

Kumar R, Dahal P, Singh-Phulgenda S, Siddiqui NA, Munir A,  et al.
2023-10-28 • BMJ Open
2023-10-28 • BMJ Open
INTRODUCTION
Visceral leishmaniasis (VL) is a parasitic disease with an estimated 30 000 new cases occurring annually. There is an observed variation in the efficacy of the current f...
Journal Article
|
Editorial

Therapeutic strategies against leishmania and trypanosoma

Santos ALS, Rodrigues IA, d’Avila-Levy CM, Sodré CL, Ritmeijer KKD,  et al.
2023-10-19 • Pathogens
2023-10-19 • Pathogens
Human African trypanosomiasis (also known as sleeping sickness, with Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense as etiological agents), American trypanosomiasis (als...
Journal Article
|
Research

Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis

Verrest L, Roseboom IC, Wasunna M, Mbui J, Njenga SN,  et al.
2023-09-20 • Journal of Antimicrobial Chemotherapy
2023-09-20 • Journal of Antimicrobial Chemotherapy
OBJECTIVES
To improve visceral leishmaniasis (VL) treatment in Eastern Africa, 14- and 28-day combination regimens of paromomycin plus allometrically dosed miltefosine were evaluated...
Journal Article
|
Research

Host preference and human blood index of Phlebotomus orientalis, an exophilic sand fly vector of visceral leishmaniasis in eastern Sudan

Jibreel T, Khogali A, Jiménez M, Raiyed A, Dakein O,  et al.
2023-08-04 • Medical and Veterinary Entomology
2023-08-04 • Medical and Veterinary Entomology
Visceral leishmaniasis (VL, kala azar), caused by Leishmania donovani, transmitted by Phlebotomus orientalis, is a serious systemic disease that causes high morbidity and mortality rates...